Worldwide Business with kathy ireland® Interview with Keystone Heart
Worldwide Business with kathy ireland® Highlights A Revolutionary Device Being Developed by Keystone Heart to Protect the Brain During Cardiovascular Procedures
Tune in to Bloomberg International on Sunday, April 2, 2017. See market-by-market listings below.
Los Angeles, CA – March 28 2017 — Worldwide Business with kathy ireland® announces an exclusive Interview featuring Keystone Heart, a medical device company that develops and manufactures cerebral embolic protection devices intended to reduce the risk of stroke, neurocognitive decline and dementia caused by brain emboli associated with cardiovascular procedures.
President and CEO Chris Richardson will discuss the company’s mission of protecting the brain from damage during cardiovascular procedures.
“TAVR procedures save lives, and we are working to preserve quality of life for TAVR patients,” said Richardson.
While strokes are among the most feared and costly complications of cardiovascular interventions, newer diagnostics demonstrate that minor damage to the brain can result from these procedures, and this damage can affect the patient’s processing speed and executive function as well as fundamental functions such memory, language, and balance.
Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research.Research conducted by members of the Yale Cardiovascular Research Group demonstrate that Keystone’s TriGuard™ Cerebral Embolic Protection Device, provides protection for all three arteries which provide blood flow to the brain, and also showed significant reduction of all stroke and neurologic decline.
Richardson says that Keystone Heart is focused on advancing their medical solutions to help countless patients undergoing cardiovascular procedures in the future. He explains, “Effective January 1 of this year, we’re launching throughout the European marketplace. This will enable us to provide cerebral embolic protection for patients undergoing cardiac procedures in Europe.”
“In the United States, we’ll complete our trial by July and then tabulate the data, submit it to the FDA and are hopeful for marketing approval in the first quarter of 2018.”
JL Haber, Vice President of Programming for Worldwide Business with kathy ireland®, is proud to feature Keystone Heart. He says, “Cerebral function is the essence of quality of life. As a result, protecting the brain during medical procedures is a key component to patient success. No one does this like Keystone Heart and their experienced, knowledgeable management team. Their message is an important one to share, and we’re so excited to have this inspiring company on our show.”
About The TriGuard™ Cerebral Embolic Protection Device
Keystone Heart’s TriGuard is the only cerebral protection device designed to provide full coverage to all brain territories to minimize the risk of cerebral damage during TAVR and other cardiovascular procedures. The CE marked TriGuard device is shaped to accommodate anatomic variations of the aortic arch. Formed to withstand potential interface with the TAVR delivery system and other procedure related accessories, it uses a Nitinol® frame and mesh — flexible and atraumatic, yet robust and sturdy.
The TriGuard Cerebral Embolic Protection Device is placed via one of two femoral artery access ports typically used in TAVR, thereby eliminating the need for a third puncture site. It deploys rapidly, and self-positions through a small 9F catheter. TriGuard provides stable, atraumatic protection, with simple retrieval.
The TriGuard Cerebral Embolic Protection Device has been granted the CE Mark in the European Union and is commercially available in Europe. In the United States, the device is currently available for investigational use only.
About Keystone Heart
Keystone Heart Ltd. is a medical device company developing and manufacturing cerebral embolic protection devices intended to reduce the risk of brain embolization associated with cardiovascular procedures.
The company is focused on protecting the brain from emboli to reduce the risk of brain infarcts during TAVR, atrial fibrillation ablation and other cardiovascular procedures. The TriGuard product pipeline is designed to help interventional cardiologists, electrophysiologists and cardiac surgeons to preserve brain reserve while performing these procedures.
Headquartered in Israel with US operations in Tampa, FL, Keystone Heart is dedicated to advancing patient care through innovative technology and clinical research. The company’s management has extensive experience in the fields of interventional cardiology and medical devices. For additional information, please contact us or visit: www.keystoneheart.com.
About Worldwide Business with kathy ireland®
Worldwide Business with kathy ireland® is a weekly business television program featuring real world insights from corporate executives from all over the globe which can be viewed on Fox Business Network as part of their sponsored programming lineup, as well as internationally to over 50 countries on Bloomberg International.
Visit www.tvwwb.com for detailed airing schedules or check local listings.